Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus

• References

• 1 Nicolucci A, De Berardis G, Sacco M. et al. AHA/ ADA vs ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions.. Eur Heart J 2007; 28: 1925-1927.
• 2 Collaborative Group of the Primary Prevention Project (PPP).. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice.. Lancet 2001; 357: 89-95.
• 3 Ridker PM, Ridker PM, Cook NR. et al. Low-Dose Aspirin and Primary Prevention in Women.. N Engl J Med 2005; 352: 1293-1304.
• 4 Ogawa H, Nakayama M, Morimoto T. et al. Low-dose aspirin for primary prevention of athero-sclerotic events in patients with type 2 diabetes: a randomized controlled trial.. J Am Med Assoc 2008; 300: 2134-2141.
• 5 Belch J, MacCuish A, Campbell I. et al. Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh.. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.. Br Med J 2008; 337: a1840.
• 6 Fowkes FG, Price JF, Stewart MC. et al. Aspirin for Asymptomatic Atherosclerosis Trialists.. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial.. J Am Med Assoc 2010; 303: 841-848.
• 7 Hirsch AT, Criqui MH, Treat-Jacobson D. et al. Peripheral arterial disease detection, awareness, and treatment in primary care.. J Am Med Assoc 2001; 286: 1317-1324.
• 8 Antithrombotic Trialists’ Collaboration.. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.. Br Med J 2002; 324: 71-86.
• 9 De Berardis G, Sacco M, Strippoli GF. et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials.. Br Med J 2009; 339: b4531.
• 10 Antithrombotic Trialists’ (ATT) Collaboration. Baigent C, Blackwell L, Collins R. et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.. Lancet 2009; 373: 1849-1860.
• 11 Fujishima M, Kiyohara Y, Kato I. et al. Diabetes and cardiovascular disease in a prospective population survey in Japan: the Hisayama Study.. Diabetes 1996; 45: S14-S16.
• 12 Tominaga M, Eguchi H, Manaka H. et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study.. Diabetes Care 1999; 22: 920-924.
• 13 Malmström RE, Settergren M, Böhm F. et al. No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance.. Thromb Haemost 2009; 101: 157-164.
• 14 Action to Control Cardiovascular Risk in Diabetes Study Group. Gerstein HC, Miller ME, Byington RP. et al. Effects of intensive glucose lowering in type 2 diabetes.. N Engl J Med 2008; 358: 2545-2559.
• 15 ADVANCE Collaborative Group. Patel A, MacMahon S, Chalmers J. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.. N Engl J Med 2008; 358: 2560-2572.
• 16 Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes.. J Am Med Assoc 2004; 291: 335-342.
• 17 Lanas A, Sekar MC, Hirschowitz BI. Objective evidence of aspirin use in both ulcer and nonulcer upper and lower gastrointestinal bleeding.. Gastroenterology 1992; 103: 862-869.
• 18 MacDonald TM, Morant SV, Robinson GC. et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study.. Br Med J 1997; 315: 1333-1337.
• 19 Morimoto T, Fukui T, Lee TH. et al. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.. Am J Med 2004; 117: 459-468.
• 20 Gorin L, Fauchier L, Nonin E. et al. Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1.. Thromb Haemost 2010; 103: 833-840.
• 21 Healey JS. Pro: “Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation”.. Thromb Haemost 2009; 102: 912-913.
• 22 Lip GY, Nieuwlaat R, Pisters R. et al. @ @Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.. Chest 2010; 137: 263-272.
• 23 Lip GY. Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at ‘moderate risk’ [CHADS2 score=1]: simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice.. Thromb Haemost 2010; 103: 683-685.
• 24 ACCORD Study Group. Cushman WC, Evans GW, Byington RP. et al. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus.. N Engl J Med 2010; 362: 1575-1585.
• 25 Pignone M, Alberts MJ, Colwell JA. et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation.. Circulation 2010; 121: 2694-2701.
• 26 De Berardis G, Sacco M, Evangelista V. et al. ACCEPT-D Study Group.. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins.. Trials 2007; 8: 21-29.